Search
Chromium
go.drugbank.com/drugs/DB11136ApprovedInvestigationalChromium chloride is available as an intravenous injection for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) [FDA Label]. … According to the National Institute of Health, the daily dietary reference intake (DRI) of chromium for adult male and non-pregnant female are 35 μg and 25 μg, respectively [L1986].
Mixtures: For-2, Doctor's Choice Brand for MenNaftifine
go.drugbank.com/drugs/DB00735ApprovedNaftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseRusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigational[L64113] It is the first hepcidin mimetic approved for polycythemia vera.[L64113] … [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.
Bulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigational[A226340,L30235] Until recently, there have been extremely limited treatments available for Hepatitis D infection. … It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseTheophylline
go.drugbank.com/drugs/DB00277ApprovedInvestigationalTheophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.
Categories: Drugs for Obstructive Airway DiseasesCilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalCilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [A243351, A243361, L39411] Cilgavimab is not approved for any indication by the FDA.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseTixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalTixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [A243351, A243361, L39411] Tixagevimab is not approved for any indication by the FDA.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseAnthralin
go.drugbank.com/drugs/DB11157ApprovedThe chemical structure of anthralin allows for dual solubility, permitting the compound to be absorbed well through the epidermis [A27276]. … It is a main active ingredient in topical skin formulations for the treatment of psoriasis. Various formulations of the drug are available, including solutions, foams, and shampoos [L1979].
Categories: Antipsoriatics for Topical UseFostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalFostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). … It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].
Categories: Experimental Unapproved Treatments for COVID-19Edoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigationalThis has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. … Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for